Boehringer Ingelheim (Germany) forms new company:
This article was originally published in Clinica
Boehringer Ingelheim (Germany) has merged certain bioproducts businesses to form a separate company, Boehringer Ingelheim Bioproducts Partnership. Focusing on in vitro diagnostics and bioproducts, it will be based in Heidelberg. The new company comprises Serva Feinbiochemica (Germany), Bender MedSystems (Austria), Boehringer Ingelheim-BioWhittaker Partnership (Belgium) and BioWhittaker (France). Ingelheim Diagnostica y Tecnologia (Spain) will be incorporated during 1997. Sales of the new company are expected to reach DM 70 million ($48 million) in 1996.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.